Callan Family Office LLC Purchases New Stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Callan Family Office LLC purchased a new stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 58,040 shares of the company’s stock, valued at approximately $92,000.

Several other hedge funds have also recently bought and sold shares of RAPT. Los Angeles Capital Management LLC raised its holdings in RAPT Therapeutics by 138.1% in the third quarter. Los Angeles Capital Management LLC now owns 201,439 shares of the company’s stock valued at $405,000 after buying an additional 116,853 shares during the period. Readystate Asset Management LP purchased a new position in RAPT Therapeutics in the third quarter valued at approximately $36,000. Barclays PLC raised its holdings in RAPT Therapeutics by 277.2% in the third quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after buying an additional 29,195 shares during the period. JPMorgan Chase & Co. raised its holdings in RAPT Therapeutics by 298.2% in the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after buying an additional 25,130 shares during the period. Finally, SG Americas Securities LLC raised its holdings in RAPT Therapeutics by 401.9% in the fourth quarter. SG Americas Securities LLC now owns 53,244 shares of the company’s stock valued at $84,000 after buying an additional 42,636 shares during the period. Hedge funds and other institutional investors own 99.09% of the company’s stock.

Wall Street Analysts Forecast Growth

RAPT has been the topic of several research reports. Wells Fargo & Company cut their price target on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a report on Tuesday, November 12th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of RAPT Therapeutics in a research note on Monday. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $2.00 price objective (down previously from $7.00) on shares of RAPT Therapeutics in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, RAPT Therapeutics has a consensus rating of “Hold” and an average price target of $5.29.

RAPT Therapeutics Price Performance

RAPT opened at $1.14 on Wednesday. The stock has a market capitalization of $39.85 million, a PE ratio of -0.41 and a beta of -0.31. The firm’s fifty day moving average price is $1.23 and its 200 day moving average price is $1.53. RAPT Therapeutics, Inc. has a 12-month low of $0.79 and a 12-month high of $9.65.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.69). On average, equities research analysts forecast that RAPT Therapeutics, Inc. will post -2.14 earnings per share for the current fiscal year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.